ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
GRPa-PRS: A risk stratification method to identify genetically-regulated pathways in polygenic diseases.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Genetic Burden andJournal of personalized medicine · 2026Article
- GRPa-PRS: A risk stratification method to identify genetically-regulated pathways in polygenic diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- iGTP: learning interpretable cellular embedding for inferring biological mechanisms underlying single-cell transcriptomics.Briefings in bioinformatics · 2025Article
- Article
- scEMB: Learning context representation of genes based on large-scale single-cell transcriptomics.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
introductionPolygenic risk score (PRS) assesses genetic risk for diseases, yet some high-risk individuals avoid illness while low-risk individuals develop it. We hypothesize that unknown counterfactors may reverse PRS predictions, offering insights into disease mechanisms and interventions.
methodsWe developed a novel framework to identify genetically-regulated pathways (GRPas) using PRS-based stratification in Alzheimer's disease (AD) and schizophrenia (SCZ) cohorts. We calculated PRS models, stratified individuals by risk and diagnosis, and analyzed differential GRPas. For AD, analyses were further conducted with and without apolipoprotein E (APOE) effects, and across APOE haplotype.
resultsIn AD, we identified several well-known AD-related pathways, including amyloid-beta clearance, tau protein binding, and resilience-related calcium signaling pathway, and divalent inorganic cation homeostasis. DISCUSSION: Our method offers flexibility for exploring GRPas among PRS-stratified subgroups using summary statistics or individual-level data. Fewer GRPas identified in the no-APOE AD model and SCZ suggest a more polygenic architecture, necessitating larger samples to detect significant GRPas. HIGHLIGHTS: Characterize genetically-regulated expression (GReX) among groups stratified by polygenic risk score (PRS) Leverage GReX and PRS to explore the resilience and susceptibility at the pathway level Highlight calcium signaling and cation homeostasis functions linked to resilience Enable personalized prevention by reinforcing the different resilience factors present or absent in each individual Our genetically-regulated pathway (GRPa) -PRS framework can be further expanded to other complex polygenic traits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.